Earnings Ahead

SRPT - Sarepta Therapeutics Inc.

106.4 -1.88 -1.74

Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc.

About

Profile

Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.


Headquarters

Cambridge, Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

SRPT

Shares plunged 35% after the biotechnology company said a late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal.


 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Elanco Animal Health set to join S&P MidCap 400, Sarepta to join S&P SmallCap 600
  • Sarepta Therapeutics refinances $700M of convertible notes
  • Sarepta sells Arrowhead stock, activates $100M milestone payment
  • Biotech sector slips amid reported return of ousted FDA official
  • Sarepta Therapeutics Q2 2025 Earnings Preview
  • Sarepta rises on strong quarterly earnings and revenue
  • Sarepta Therapeutics Non-GAAP EPS of $2.02 beats by $0.86, revenue of $611.1M beats by $80.06M
  • Sarepta reportedly hired Trump-linked lobbying firm after gene therapy deaths
  • Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks
  • FDA vaccines head, chief medical officer Vinay Prasad departs agency
  • Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs
  • Sarepta upgraded to Neutral at J.P. Morgan, Outperform at Oppenheimer
  • FDA recommends lifting voluntary hold on Elevidys in ambulatory patients
  • Sarepta rises 2%; Barclays downgrades to underweight on liquidity and Elevidys concerns
  • Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics
  • What’s behind Sarepta’s gene therapy deaths?
  • Sarepta denies Elevidys is linked to latest patient death in Brazil
  • Sarepta falls as FDA plans to investigate death of child who received Elevidys
  • Biggest stock movers Friday: INTC, PARA, SRPT, and more
  • EU panel declines backing Sarepta-Roche gene therapy for Duchenne

Earnings History

Date EPS / Forecast Revenue / Forecast
October 27, 2021 - / -1.83 - / 171.36M
August 4, 2021 -1.02 / -1.3 164.09M / 167.07M
May 5, 2021 -2.1 / -1.83 146.93M / 145.81M Beat!
March 1, 2021 -2.4 / -1.8 145.14M / 150.38M
November 5, 2020 -2.5 / -1.71 143.92M / 137.76M Beat!
August 5, 2020 -1.93 / -1.72 137.36M / 116.29M Beat!
May 6, 2020 -0.23 / -1.92 113.67M / 116.49M
February 26, 2020 -3.16 / -1.81 100.11M / 98.8M Beat!
November 7, 2019 -1.7 / -1.35 99.04M / 98.48M Beat!
August 7, 2019 -3.74 / -1.07 94.67M / 91.05M Beat!
May 8, 2019 -1.07 / -1.61 87.01M / 86.6M Beat!
February 27, 2019 -2.05 / -1.02 84.42M / 84.92M
October 24, 2018 -1.15 / -0.78 78.49M / 78.75M
August 8, 2018 -1.67 / -0.84 73.53M / 71.4M Beat!
May 3, 2018 -0.55 / -0.32 64.6M / 65.09M
February 26, 2018 - / -0.32 - / 55.57M
October 25, 2017 -0.76 / -0.85 45.95M / 40.77M Beat!
July 19, 2017 -0.46 / -0.77 35.01M / 22.38M Beat!
April 27, 2017 -0.71 / -0.81 16.34M / - Beat!
February 28, 2017 -0.71 / -0.45 5.42M / 46.83M
October 27, 2016 -1.18 / -0.52 - / 3.08M
Date Price Open High Low Vol Change
Dec 2 20.47 19.82
20.53
19.37
4.0M 3.80%
Dec 1 19.72 20.84
21
19.67
2.9M -7.59%
Nov 28 21.34 21.12
21.38
20.72
1.6M 1.86%
Nov 26 20.95 19.4
21.21
19.35
3.2M 8.27%
Nov 25 19.35 18.91
19.45
18.73
3.0M 2.33%
 
Nov 24 18.91 17.76
19.14
17.61
4.4M 6.90%
Nov 21 17.69 16.4
17.72
16.33
3.9M 7.34%
Nov 20 16.48 16.69
17.6
16.31
4.6M 0.55%
Nov 19 16.39 17.41
17.43
15.94
4.4M -6.02%
Nov 18 17.44 17.38
17.73
16.94
3.7M -0.57%
Nov 17 17.54 18.61
18.7
17.38
4.5M -6.75%
Nov 14 18.81 17.51
20.15
17.51
8.0M 5.56%
Nov 13 17.82 17.69
18.35
17.5
3.5M -1%
Nov 12 18 18.05
18.63
17.6
4.1M 0.11%
Nov 11 17.98 17.27
18.3
16.9
4.4M 4.11%
Nov 10 17.27 18.13
18.13
17.26
3.5M -2.04%
Nov 7 17.63 17.77
17.95
16.55
4.2M -0.06%
Nov 6 17.64 18.64
18.75
17.41
6.6M -5.52%
Nov 5 18.67 16.59
18.8
16.58
11.1M 15.25%
Nov 4 16.2 15.24
17.75
15.08
23.9M -33.74%
Nov 3 24.45 24.27
24.55
22.67
15.6M 1.83%
Oct 31 24.01 23.42
24.48
23.02
4.5M 3.27%
Oct 30 23.25 23.22
23.39
22.79
3.4M -0.85%
Oct 29 23.45 24.02
24.09
23.15
3.7M -3.18%
Oct 28 24.22 23.48
24.4
23.27
3.4M 3.06%
Oct 27 23.5 23.28
24.24
23.06
4.0M 3.02%
Oct 24 22.81 21.94
23.43
21.8
3.7M 4.20%
Oct 23 21.89 21.8
22.27
21.29
4.5M -2.58%
Oct 22 22.47 23.2
23.72
22.29
3.7M -3.77%
Oct 21 23.35 23.07
23.54
22.77
2.9M 1.30%
Oct 20 23.05 23
23.73
22.8
4.0M 2.40%
Oct 17 22.51 22.83
22.99
21.93
4.5M -3.56%
Oct 16 23.34 22.25
23.87
22.22
6.1M 5.14%
Oct 15 22.2 21.74
22.26
21.52
3.5M 3.59%
Oct 14 21.43 21.58
21.82
20.92
3.7M -2.41%
Oct 13 21.96 22
22.48
21.5
4.0M -0.68%
Oct 10 22.11 23.15
23.19
22.09
4.6M -4.41%
Oct 9 23.13 23.44
24.18
23.05
5.3M -1.07%
Oct 8 23.38 24.18
25.32
22.64
10.5M 1.12%
Oct 7 23.12 23.36
23.88
22.56
4.8M -0.6%
Oct 6 23.26 23.15
23.59
22.31
6.2M 2.74%
Oct 3 22.64 22.37
22.95
21.82
8.3M 1.30%
Oct 2 22.35 19.57
23.42
19.57
15.4M 15.68%
Oct 1 19.32 18.88
20.05
18.88
4.7M 0.26%
Sep 30 19.27 18.67
19.34
18.14
5.5M 2.39%
Sep 29 18.82 18.17
19.28
18.14
6.6M 2.51%
Sep 26 18.36 17.64
18.39
17.57
4.1M 3.61%
Sep 25 17.72 18.09
18.24
17.65
4.3M -2.96%
Sep 24 18.26 18.15
18.46
17.51
5.1M 1.84%
Sep 23 17.93 18.72
19.05
17.88
5.6M -3.86%
Sep 22 18.65 18.5
19.48
18.05
9.1M 7%
Sep 19 17.43 18.61
18.72
17.4
6.9M -5.89%
Sep 18 18.52 17.28
18.55
17.06
6.9M 8.62%
Sep 17 17.05 18
18.14
17.05
6.6M -5.8%
Sep 16 18.1 17.86
18.84
17.76
6.4M 3.61%
Sep 15 17.47 17.47
18.27
17.23
5.1M 0.46%
Sep 12 17.39 17.97
18.21
17.23
3.5M -2.9%
Sep 11 17.91 17.2
17.95
16.85
6.1M 4.01%
Sep 10 17.22 17.66
17.9
17.2
5.8M -2.38%
Sep 9 17.64 17.72
17.87
17.44
5.1M 0%